Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relaps...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2024-03, Vol.18 (3), p.e0012035-e0012035 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0012035 |
|---|---|
| container_issue | 3 |
| container_start_page | e0012035 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 18 |
| creator | Kostka, Julia Maharjan, Anu S Kumar, Sanjai Hackenyos, Douglas Krause, Peter J Dieckhaus, Kevin |
| description | Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG.
The presence of B. microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples was then tested for B. microti antibodies using an enzyme linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, and 52 samples tested using ELISA, none were positive for B. microti antibodies.
Commercially available IVIG may not be of therapeutic benefit for babesiosis patients. Additional sampling of IVIG for B. microti antibody and a clinical trial of babesiosis patients given IVIG compared with controls would provide further insight into the use of IVIG for the treatment of babesiosis. |
| doi_str_mv | 10.1371/journal.pntd.0012035 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3069183489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A788777743</galeid><doaj_id>oai_doaj_org_article_f1d8bd596b084643acaf81c48b377bfe</doaj_id><sourcerecordid>A788777743</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-4728c76dcfc7b969f5948fbe28c82d5c24c34175000d44635a21816fc752a91a3</originalsourceid><addsrcrecordid>eNptklGP1CAUhRujcdfVf2C0iYlZH2aEAgWezLjRdZJNfFHjGwEKM0wojNBusv9e6nQ3M2bLQ9vLdw9wOFX1GoIlRBR-3MUxBemX-zB0SwBgAxB5Up1DjsiioYg8Pfo-q17kvAOAcMLg8-oMMcwwgOC8-r1S2QRt6mjrVRjc4rNUJjtZ906nOLhalqKK3V3tQq1j35uknfTlb0jy1oQ45tr1_Rjixkc1-kJdrn-trz-8rJ5Z6bN5Nb8vqp9fv_y4-ra4-X69vlrdLDSheFhg2jBN205bTRVvuSUcM6tMqbKmI7rBGmFICQCgw7hFRDaQwbbQpJEcSnRRvT3o7n3MYjYlCwRaDhnCjBdifSC6KHdin1wv052I0ol_hZg2QqbBaW-EhR1THeGtAgy3GEktLYMaM4UoVdYUrU_zaqPqTafNZIM_ET2dCW4rNvFWQMBbAjApCpezQop_RpMH0busjfcymGKmaMoVNcUIPm383X_o48ebqY0sJ3DBxrKwnkTFijJGy4NRoZaPUGV0ptx0DMa6Uj9peH_UsDXSD9sc_Ti4GPIpiA9gyUvOydgHNyAQU1Lvdy2mpIo5qaXtzbGTD0330UR_AZ305D0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3069183489</pqid></control><display><type>article</type><title>Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kostka, Julia ; Maharjan, Anu S ; Kumar, Sanjai ; Hackenyos, Douglas ; Krause, Peter J ; Dieckhaus, Kevin</creator><contributor>Ionica, Angela Monica</contributor><creatorcontrib>Kostka, Julia ; Maharjan, Anu S ; Kumar, Sanjai ; Hackenyos, Douglas ; Krause, Peter J ; Dieckhaus, Kevin ; Ionica, Angela Monica</creatorcontrib><description>Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG.
The presence of B. microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples was then tested for B. microti antibodies using an enzyme linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, and 52 samples tested using ELISA, none were positive for B. microti antibodies.
Commercially available IVIG may not be of therapeutic benefit for babesiosis patients. Additional sampling of IVIG for B. microti antibody and a clinical trial of babesiosis patients given IVIG compared with controls would provide further insight into the use of IVIG for the treatment of babesiosis.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0012035</identifier><identifier>PMID: 38484010</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antibodies ; Antibodies, Protozoan ; Antibody response ; Antigens ; Asymptomatic infection ; B cells ; Babesia microti ; Babesiosis ; Babesiosis - drug therapy ; Biology and Life Sciences ; Care and treatment ; Diagnosis ; ELISA ; Enzyme-Linked Immunosorbent Assay ; Enzymes ; Flow cytometry ; Health aspects ; Health services ; Human subjects ; Humans ; Immunocompromised hosts ; Immunofluorescence ; Immunoglobulins ; Immunoglobulins, Intravenous - therapeutic use ; Infection ; Infections ; Intravenous administration ; Lymphoma ; Medicine and Health Sciences ; Monoclonal antibodies ; Patient outcomes ; Patients ; Protozoa ; Protozoal infections ; Research and Analysis Methods</subject><ispartof>PLoS neglected tropical diseases, 2024-03, Vol.18 (3), p.e0012035-e0012035</ispartof><rights>Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c574t-4728c76dcfc7b969f5948fbe28c82d5c24c34175000d44635a21816fc752a91a3</cites><orcidid>0000-0002-8347-4900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965045/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965045/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38484010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ionica, Angela Monica</contributor><creatorcontrib>Kostka, Julia</creatorcontrib><creatorcontrib>Maharjan, Anu S</creatorcontrib><creatorcontrib>Kumar, Sanjai</creatorcontrib><creatorcontrib>Hackenyos, Douglas</creatorcontrib><creatorcontrib>Krause, Peter J</creatorcontrib><creatorcontrib>Dieckhaus, Kevin</creatorcontrib><title>Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG.
The presence of B. microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples was then tested for B. microti antibodies using an enzyme linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, and 52 samples tested using ELISA, none were positive for B. microti antibodies.
Commercially available IVIG may not be of therapeutic benefit for babesiosis patients. Additional sampling of IVIG for B. microti antibody and a clinical trial of babesiosis patients given IVIG compared with controls would provide further insight into the use of IVIG for the treatment of babesiosis.</description><subject>Antibodies</subject><subject>Antibodies, Protozoan</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Asymptomatic infection</subject><subject>B cells</subject><subject>Babesia microti</subject><subject>Babesiosis</subject><subject>Babesiosis - drug therapy</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>ELISA</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Enzymes</subject><subject>Flow cytometry</subject><subject>Health aspects</subject><subject>Health services</subject><subject>Human subjects</subject><subject>Humans</subject><subject>Immunocompromised hosts</subject><subject>Immunofluorescence</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Infection</subject><subject>Infections</subject><subject>Intravenous administration</subject><subject>Lymphoma</subject><subject>Medicine and Health Sciences</subject><subject>Monoclonal antibodies</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Protozoa</subject><subject>Protozoal infections</subject><subject>Research and Analysis Methods</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNptklGP1CAUhRujcdfVf2C0iYlZH2aEAgWezLjRdZJNfFHjGwEKM0wojNBusv9e6nQ3M2bLQ9vLdw9wOFX1GoIlRBR-3MUxBemX-zB0SwBgAxB5Up1DjsiioYg8Pfo-q17kvAOAcMLg8-oMMcwwgOC8-r1S2QRt6mjrVRjc4rNUJjtZ906nOLhalqKK3V3tQq1j35uknfTlb0jy1oQ45tr1_Rjixkc1-kJdrn-trz-8rJ5Z6bN5Nb8vqp9fv_y4-ra4-X69vlrdLDSheFhg2jBN205bTRVvuSUcM6tMqbKmI7rBGmFICQCgw7hFRDaQwbbQpJEcSnRRvT3o7n3MYjYlCwRaDhnCjBdifSC6KHdin1wv052I0ol_hZg2QqbBaW-EhR1THeGtAgy3GEktLYMaM4UoVdYUrU_zaqPqTafNZIM_ET2dCW4rNvFWQMBbAjApCpezQop_RpMH0busjfcymGKmaMoVNcUIPm383X_o48ebqY0sJ3DBxrKwnkTFijJGy4NRoZaPUGV0ptx0DMa6Uj9peH_UsDXSD9sc_Ti4GPIpiA9gyUvOydgHNyAQU1Lvdy2mpIo5qaXtzbGTD0330UR_AZ305D0</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Kostka, Julia</creator><creator>Maharjan, Anu S</creator><creator>Kumar, Sanjai</creator><creator>Hackenyos, Douglas</creator><creator>Krause, Peter J</creator><creator>Dieckhaus, Kevin</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8347-4900</orcidid></search><sort><creationdate>20240301</creationdate><title>Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)</title><author>Kostka, Julia ; Maharjan, Anu S ; Kumar, Sanjai ; Hackenyos, Douglas ; Krause, Peter J ; Dieckhaus, Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-4728c76dcfc7b969f5948fbe28c82d5c24c34175000d44635a21816fc752a91a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies</topic><topic>Antibodies, Protozoan</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Asymptomatic infection</topic><topic>B cells</topic><topic>Babesia microti</topic><topic>Babesiosis</topic><topic>Babesiosis - drug therapy</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>ELISA</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Enzymes</topic><topic>Flow cytometry</topic><topic>Health aspects</topic><topic>Health services</topic><topic>Human subjects</topic><topic>Humans</topic><topic>Immunocompromised hosts</topic><topic>Immunofluorescence</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Infection</topic><topic>Infections</topic><topic>Intravenous administration</topic><topic>Lymphoma</topic><topic>Medicine and Health Sciences</topic><topic>Monoclonal antibodies</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Protozoa</topic><topic>Protozoal infections</topic><topic>Research and Analysis Methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kostka, Julia</creatorcontrib><creatorcontrib>Maharjan, Anu S</creatorcontrib><creatorcontrib>Kumar, Sanjai</creatorcontrib><creatorcontrib>Hackenyos, Douglas</creatorcontrib><creatorcontrib>Krause, Peter J</creatorcontrib><creatorcontrib>Dieckhaus, Kevin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kostka, Julia</au><au>Maharjan, Anu S</au><au>Kumar, Sanjai</au><au>Hackenyos, Douglas</au><au>Krause, Peter J</au><au>Dieckhaus, Kevin</au><au>Ionica, Angela Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>18</volume><issue>3</issue><spage>e0012035</spage><epage>e0012035</epage><pages>e0012035-e0012035</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>Babesiosis is a worldwide emerging protozoan infection that is associated with a spectrum of disease severity from asymptomatic infection to severe organ damage and death. While effective treatment strategies are available, some immunocompromised patients experience severe acute and prolonged/relapsing illness due in part to an impaired host antibody response. Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some immunocompromised babesiosis patients, but its therapeutic effect is uncertain. We evaluated the presence of Babesia microti antibodies in commercial samples of IVIG.
The presence of B. microti antibodies in commercial samples of IVIG were tested using an immunofluorescence assay. A subset of samples was then tested for B. microti antibodies using an enzyme linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, and 52 samples tested using ELISA, none were positive for B. microti antibodies.
Commercially available IVIG may not be of therapeutic benefit for babesiosis patients. Additional sampling of IVIG for B. microti antibody and a clinical trial of babesiosis patients given IVIG compared with controls would provide further insight into the use of IVIG for the treatment of babesiosis.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>38484010</pmid><doi>10.1371/journal.pntd.0012035</doi><orcidid>https://orcid.org/0000-0002-8347-4900</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2024-03, Vol.18 (3), p.e0012035-e0012035 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_3069183489 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies Antibodies, Protozoan Antibody response Antigens Asymptomatic infection B cells Babesia microti Babesiosis Babesiosis - drug therapy Biology and Life Sciences Care and treatment Diagnosis ELISA Enzyme-Linked Immunosorbent Assay Enzymes Flow cytometry Health aspects Health services Human subjects Humans Immunocompromised hosts Immunofluorescence Immunoglobulins Immunoglobulins, Intravenous - therapeutic use Infection Infections Intravenous administration Lymphoma Medicine and Health Sciences Monoclonal antibodies Patient outcomes Patients Protozoa Protozoal infections Research and Analysis Methods |
| title | Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T23%3A36%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Absence%20of%20Anti-Babesia%20microti%20antibody%20in%20commercial%20intravenous%20immunoglobulin%20(IVIG)&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Kostka,%20Julia&rft.date=2024-03-01&rft.volume=18&rft.issue=3&rft.spage=e0012035&rft.epage=e0012035&rft.pages=e0012035-e0012035&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0012035&rft_dat=%3Cgale_plos_%3EA788777743%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3069183489&rft_id=info:pmid/38484010&rft_galeid=A788777743&rft_doaj_id=oai_doaj_org_article_f1d8bd596b084643acaf81c48b377bfe&rfr_iscdi=true |